Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asciminib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asciminib SCHEMBL15388308 | 1.00 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL15388554 | 1.00 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL15388306 | 1.00 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL22656445 | 0.99 | ABL1 (0.98) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL22655431 | 0.99 | ABL1 (0.98) | ABL1BCRKCNH2CRBN | |
| SCHEMBL16678695 | 0.96 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393486 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393510 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393484 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393374 | 0.94 | ABL1 (1.00) | ABL1BCRKCNH2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3969445-B1 | PROCESS FOR THE PREPARATION OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE | NOVARTIS AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| EP-3969445-A1 | CHEMICAL PROCESS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096529-A | Chemical process | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |